|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/11/18 Emmaus Life Sciences, Inc. 10-K 9/30/18 77:6.9M S2 Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 930K
2: EX-10.13 Material Contract HTML 54K
3: EX-10.14 Material Contract HTML 53K
4: EX-10.15 Material Contract HTML 37K
5: EX-23.1 Consent of Experts or Counsel HTML 21K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
16: R1 Document and Entity Information HTML 58K
17: R2 Consolidated Balance Sheets HTML 126K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 49K
19: R4 Consolidated Statements of Operations HTML 78K
20: R5 Consolidated Statements of Changes in Equity HTML 104K
21: R6 Consolidated Statements of Cash Flows HTML 119K
22: R7 Consolidated Statements of Cash Flows HTML 24K
(Parenthetical)
23: R8 Nature of Operations HTML 32K
24: R9 Summary of Significant Accounting Policies HTML 90K
25: R10 Accounts Receivable, Net HTML 27K
26: R11 Long - Term Borrowings and Other Note Payables HTML 26K
27: R12 Acquisition HTML 47K
28: R13 Stockholders' Equity HTML 207K
29: R14 Convertible Preferred Stock HTML 39K
30: R15 Income Taxes HTML 67K
31: R16 Related Party Transactions HTML 29K
32: R17 Loss Per Share HTML 37K
33: R18 Commitments and Contingent Liabilities HTML 33K
34: R19 Significant Customers HTML 23K
35: R20 Subsequent Events HTML 32K
36: R21 Summary of Significant Accounting Policies HTML 165K
(Policies)
37: R22 Summary of Significant Accounting Policies HTML 26K
(Tables)
38: R23 Accounts Receivable, Net (Tables) HTML 28K
39: R24 Acquisition (Tables) HTML 46K
40: R25 Stockholders' Equity (Tables) HTML 176K
41: R26 Income Taxes (Tables) HTML 67K
42: R27 Loss Per Share (Tables) HTML 37K
43: R28 Commitments and Contingent Liabilities (Tables) HTML 28K
44: R29 Nature of Operations (Details Narrative) HTML 32K
45: R30 Summary of Significant Accounting Policies HTML 32K
(Details )
46: R31 Summary of Significant Accounting Policies HTML 31K
(Details Narrative)
47: R32 Summary of Significant Accounting Policies HTML 71K
(Details Narrative 1)
48: R33 Accounts Receivable, Net (Details) HTML 29K
49: R34 Long - Term Borrowings and Other Note Payables HTML 48K
(Details Narrative)
50: R35 Acquisition (Details) HTML 67K
51: R36 Acquisition (Details 1) HTML 29K
52: R37 Acquisition (Details Narrative) HTML 57K
53: R38 Stockholders' Equity (Details) HTML 34K
54: R39 Stockholders' Equity (Details 1) HTML 27K
55: R40 Stockholders' Equity (Details 2) HTML 56K
56: R41 Stockholders' Equity (Details 3) HTML 123K
57: R42 Stockholders' Equity (Details 4) HTML 50K
58: R43 Stockholders' Equity (Details 5) HTML 34K
59: R44 Stockholders' Equity (Details 6) HTML 43K
60: R45 Stockholders' Equity (Details 7) HTML 63K
61: R46 Stockholders' Equity (Details Narrative) HTML 215K
62: R47 Stockholders' Equity (Details Narrative 1) HTML 101K
63: R48 Convertible Preferred Stock (Details Narrative) HTML 59K
64: R49 Income Taxes (Details) HTML 45K
65: R50 Income Taxes (Details 1) HTML 40K
66: R51 Income Taxes (Details 2) HTML 44K
67: R52 Income Taxes (Details 3) HTML 42K
68: R53 Income Taxes (Details Narrative) HTML 36K
69: R54 Related Party Transactions (Details Narrative) HTML 61K
70: R55 Loss Per Share (Details) HTML 48K
71: R56 Commitments and Contingent Liabilities (Details) HTML 25K
72: R57 Commitments and Contingent Liabilities (Details HTML 42K
Narrative)
73: R58 Significant Customers (Details Narrative) HTML 31K
74: R59 Subsequent Events (Details Narrative) HTML 60K
76: XML IDEA XML File -- Filing Summary XML 131K
75: EXCEL IDEA Workbook of Financial Reports XLSX 100K
10: EX-101.INS XBRL Instance -- mynd-20180930 XML 1.87M
12: EX-101.CAL XBRL Calculations -- mynd-20180930_cal XML 199K
13: EX-101.DEF XBRL Definitions -- mynd-20180930_def XML 782K
14: EX-101.LAB XBRL Labels -- mynd-20180930_lab XML 1.28M
15: EX-101.PRE XBRL Presentations -- mynd-20180930_pre XML 1.00M
11: EX-101.SCH XBRL Schema -- mynd-20180930 XSD 198K
77: ZIP XBRL Zipped Folder -- 0001615774-18-014245-xbrl Zip 174K
Exhibit 32.1
Certification Pursuant to Section 1350 of Chapter 63
of Title 18 of the United States Code
In connection with the Annual Report on Form 10-K of MYnd Analytics, Inc. (the “Company”) for the fiscal year ended September 30, 2018, as filed with the Securities and Exchange Commission (the “Report”), I, George Carpenter, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act. |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ George Carpenter | |
| George Carpenter | |
| Chief Executive Officer (Principal Executive Officer) | |
| December 11, 2018 |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.
This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 12/11/18 | None on these Dates | ||
| For Period end: | 9/30/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/23 Emmaus Life Sciences, Inc. 10-K 12/31/22 88:18M Donnelley … Solutions/FA 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA 5/04/21 Emmaus Life Sciences, Inc. 10-K 12/31/20 97:18M ActiveDisclosure/FA 1/25/21 Emmaus Life Sciences, Inc. 10-K 12/31/19 121:29M ActiveDisclosure/FA 5/30/19 SEC UPLOAD¶ 6/27/19 2:45K Emmaus Life Sciences, Inc. 5/02/19 SEC UPLOAD¶ 6/27/19 2:53K Emmaus Life Sciences, Inc. |